595 related articles for article (PubMed ID: 27974677)
1. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
2. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
3. The histone-H3K4-specific demethylase KDM5B binds to its substrate and product through distinct PHD fingers.
Klein BJ; Piao L; Xi Y; Rincon-Arano H; Rothbart SB; Peng D; Wen H; Larson C; Zhang X; Zheng X; Cortazar MA; Peña PV; Mangan A; Bentley DL; Strahl BD; Groudine M; Li W; Shi X; Kutateladze TG
Cell Rep; 2014 Jan; 6(2):325-35. PubMed ID: 24412361
[TBL] [Abstract][Full Text] [Related]
4. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
5. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells.
Montano MM; Yeh IJ; Chen Y; Hernandez C; Kiselar JG; de la Fuente M; Lawes AM; Nieman MT; Kiser PD; Jacobberger J; Exner AA; Lawes MC
Breast Cancer Res; 2019 Dec; 21(1):138. PubMed ID: 31805991
[TBL] [Abstract][Full Text] [Related]
7. The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B.
Zhang Y; Yang H; Guo X; Rong N; Song Y; Xu Y; Lan W; Zhang X; Liu M; Xu Y; Cao C
Protein Cell; 2014 Nov; 5(11):837-50. PubMed ID: 24952722
[TBL] [Abstract][Full Text] [Related]
8. Coordinated regulation of retinoic acid signaling pathway by KDM5B and polycomb repressive complex 2.
Zhang Y; Liang J; Li Q
J Cell Biochem; 2014 Sep; 115(9):1528-38. PubMed ID: 24619877
[TBL] [Abstract][Full Text] [Related]
9. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
10. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
11. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase KDM5B is a key regulator of genome stability.
Li X; Liu L; Yang S; Song N; Zhou X; Gao J; Yu N; Shan L; Wang Q; Liang J; Xuan C; Wang Y; Shang Y; Shi L
Proc Natl Acad Sci U S A; 2014 May; 111(19):7096-101. PubMed ID: 24778210
[TBL] [Abstract][Full Text] [Related]
13. Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Wang D; Han S; Peng R; Jiao C; Wang X; Yang X; Yang R; Li X
J Exp Clin Cancer Res; 2016 Feb; 35():37. PubMed ID: 26911146
[TBL] [Abstract][Full Text] [Related]
14. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Yamane K; Tateishi K; Klose RJ; Fang J; Fabrizio LA; Erdjument-Bromage H; Taylor-Papadimitriou J; Tempst P; Zhang Y
Mol Cell; 2007 Mar; 25(6):801-12. PubMed ID: 17363312
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone demethylase KDM5B for cancer treatment.
Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the histone demethylase KDM5B and regulation of the phenotype of triple negative breast cancer.
Yeh IJ; Esakov E; Lathia JD; Miyagi M; Reizes O; Montano MM
Sci Rep; 2019 Nov; 9(1):17663. PubMed ID: 31776402
[TBL] [Abstract][Full Text] [Related]
17. KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.
Kidder BL; Hu G; Zhao K
Genome Biol; 2014 Feb; 15(2):R32. PubMed ID: 24495580
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
19. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
20. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation.
Dey BK; Stalker L; Schnerch A; Bhatia M; Taylor-Papidimitriou J; Wynder C
Mol Cell Biol; 2008 Sep; 28(17):5312-27. PubMed ID: 18591252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
